ME Jul 2023 4.000 call

OPR - OPR Delayed price. Currency in USD
0.0500
0.0000 (0.00%)
As of 01:21PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0500
Strike4.00
Expiry date2023-07-21
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume5
Open interest1.5k
  • GlobeNewswire

    23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

    Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of fiscal year 2023 (FY2023), which

  • Motley Fool

    Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

    Most biotechs don't have a diversified business model. Both 23andMe and Fulgent provide genetic testing and diagnostic services as well as perform drug development. The idea is that there's probably a competitive advantage of some kind in drug development, lurking somewhere in the reams of genetic information that the companies generate via their testing services.

  • Simply Wall St.

    Here's Why We're Not Too Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • GlobeNewswire

    New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

    66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-consumer genetic health test SUNNYVALE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with

  • GlobeNewswire

    23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

    SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast

  • GlobeNewswire

    23andMe Releases New Report Revealing Likelihood of Developing Lupus

    23andMe+ members can now gain insights on the chronic autoimmune conditionSOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the skin, joints, heart, lungs, kidneys, circulating blood cells, or brain. The report, which is powered by data from c

  • GlobeNewswire

    Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

    Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategySOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheadin

  • Yahoo Finance Video

    Why the human genome could be health care’s holy grail

    23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe

  • Yahoo Finance

    23andMe CEO: We see more opportunities in DNA partnerships

    23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.

  • Yahoo Finance Video

    3 things to watch at next week's Milken Conference

    Yahoo Finance will have special coverage of the 2023 Milken Institute Global Conference, including live interviews, exclusive insights, and more. Brian Sozzi shares the 3 biggest things he's looking for at the Milken Conference this year: 1. Finance executives are set to address turmoil in the banking sector. 2. Top CEOs share their big ideas and predictions for the future. 3. Industry leaders from around the world will give us insight into the health of the global economy. Coverage begins Monday, May 1 from The Beverly Hilton Hotel in Los Angeles, California. Featured guests include Michael Milken, Citi (C) CEO Jane Fraser, Apollo (APO) CEO Marc Rowan, Mattel (MAT) CEO Ynon Kreiz, Mondelēz (MDLZ) CEO Dirk Van De Put, Former LinkedIn CEO Reid Hoffman, former SEC Commissioner Michael Piwowar, former Google (GOOGL) CEO Eric Schmidt, 23andMe (ME) CEO Anne Wojcicki and many others.

  • Simply Wall St.

    23andMe Holding Co.'s (NASDAQ:ME) Share Price Could Signal Some Risk

    When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...

  • GlobeNewswire

    23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

    First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignanciesRecommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics an

  • GlobeNewswire

    Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

    Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between 23andMe and Morehouse School of Medicine to increase equity in genetics and genomics ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM),

  • PR Newswire

    23andMe Publishes Inaugural Environmental, Social and Governance Report

    23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today published its inaugural environmental, social and governance (ESG) report. The report outlines the Company's strategy and initiatives to ensure ethical management, promote a diverse and equitable culture, and implement sustainable business operations. The full report is available to view at LINK.

  • GlobeNewswire

    23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

    Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stro

  • Simply Wall St.

    23andMe Holding (NASDAQ:ME) shareholders have endured a 41% loss from investing in the stock a year ago

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...

  • Motley Fool

    3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks

    The artificial intelligence (AI) revolution is here, and it's going to upend the biopharma sector in ways that most investors might not have considered. The end results are impossible to predict with accuracy, but based on what's possible with the AI tools of today, investors could reap tremendous returns from companies that are aggressive with implementing AI into their workflows. Specifically, there are at least three ways that AI is going to disrupt biotech stocks in the near term.

  • GlobeNewswire

    23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

    Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presentedSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, Apri

  • Motley Fool

    AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023

    Artificial intelligence (AI) is all the rage these days, and given how rapidly the field is advancing, it's probably going to keep being the rage for quite some time -- potentially forever, if the evangelists are to be believed! While it's a bit tough to predict exactly what changes AI tools will bring about in our society, there are already quite a few businesses that are poised to benefit tremendously, and you've probably heard of some of them already. Let's examine two such companies to see how AI could power their future returns and help them compete.

  • GlobeNewswire

    New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

    92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could help lead to better outcomes for their patients75 percent of people in the US said they’d be more likely to follow their doctor’s advice if they knew their genetic profile was used to personalize their care SUNNYVALE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- A large percentage of people and doctors in the US say that using genetic testing cou

  • Motley Fool

    2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise

    The long-term thesis for Viatris (NASDAQ: VTRS) rests on its drug pipeline, researching and developing generic copies of medicines that are off-patent, with the goal of getting regulators to agree that its generics are comparable to the branded drugs they seek to emulate. Its complex injectable generics, like Glucagon for hypoglycemic disorder, will be among the biggest growth segments, along with its new ophthalmology portfolio; each segment is expected to be worth more than $1 billion in annual revenue before the end of the decade.

  • Bloomberg

    Asia’s Richest Man Mukesh Ambani to Foray Into Genome Testing with $145 Kit

    (Bloomberg) -- Billionaire Mukesh Ambani’s group is getting into genetic mapping, looking to make a health care trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market.Most Read from BloombergMeta Plans Thousands More Layoffs as Soon as This WeekUS Banks Are Finally Being Forced to Raise Rates on DepositsTrump’s Threat of a Third-Party Run Is Undercut by ‘Sore Loser’ LawsTesla Slashes Model S and X Prices for the Second Time This YearHol

  • Motley Fool

    2 High-Growth Stocks That Could Double Your Money in 5 Years or Less

    Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.

  • GlobeNewswire

    23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

    The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the human genome, dosed the first patie

  • GlobeNewswire

    23andMe to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences: Citi Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 9:30 a.m. ET in New York, NYCowen Health Care Confere